insulin drugs glp 1 receptor agaonist market GLP-1 Drug Market: the rapid growth of the diabetes and obesity GLP-1 Agonists Market Report 2025-2033,

Description

Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, and Boyd AE, 3rd

Benz, E

Cancer Types Most Studied in Relation to GLP-1 Therapy Current peer-reviewed evidence has focused on the following obesity- and metabolic-related malignancies: Endometrial cancer (consistently demonstrating the strongest protective signal) Ovarian cancer Colorectal cancer Breast cancer (particularly post-menopausal) Meningioma Hepatobiliary cancers (liver and bile duct) Pancreatic cancer Gastric cancer Thyroid cancer Multiple myeloma A Note on Metabolic Dysfunction as the Root of Cancer Predisposition One of the most clinically meaningful insights emerging from the GLP-1 cancer research is the reframing of cancer risk as fundamentally a metabolic problem

Medical research is advancing towards more personalised medical strategies, with growing acknowledgement that responses by patients to GLP-1 receptor agonists might differ markedly